SAN DIEGO–(BUSINESS WIRE)–January 3, 2018–

Critical Diagnostics, makers of the Presage® ST2 Assay and ASPECT-PLUSTM ST2 Test, each used to assist physicians within the administration of coronary heart failure sufferers, right this moment introduced it accomplished an $8.5 million fairness financing from a consortium of industry-related buyers. Proceeds will be used to proceed world commercialization efforts.

“We are happy that such a complicated group of buyers has such confidence in our future,” notes David Geliebter, Chairman of Critical Diagnostics, “We imagine it serves to underscore the founding rules which have pushed this firm over the final dozen years, particularly to enhance the care of sufferers dwelling with coronary heart failure, by providing modern options that save and enhance lives whereas lowering general healthcare prices.”

Along with the completion of this financing the Company has introduced that efficient January 1, 2018, two senior managers have taken on added obligations.

Dennis Dalangin has been promoted to Chief Executive Officer of Critical Diagnostics. Dennis has been with the Company since 2012, most not too long ago performing as Vice President, Operations and Global Marketing. Before becoming a member of Critical Diagnostics, he was Global Director for anticoagulation options at Alere. Prior to Alere, Dennis served as Manager, Global Marketing, at Philips Healthcare. Dennis has a BS in biology from Westmont College in Santa Barbara, CA.

“The future is brilliant for ST2 and Critical Diagnostics,” says Dalangin. “I’m thrilled to have this chance to assist information the corporate ahead.”

Dr. James Snider will stay in his position as President and Director whereas additionally formally named because the Chief Scientific Officer. James has intensive expertise in product growth and operations in each startup and huge firms. Prior to becoming a member of Critical Diagnostics, James was the Executive Vice President of Business & Operations for IntelligentMD, an early-stage medical gadget firm that targeted on the important parts of illness diagnostics and therapeutic intervention. Previously, he spent eight years at Applied Biosystems (ABI). James holds a B.S. in chemistry from Grand Valley State University and a Ph.D. in chemistry from the University of South Carolina.

“We have completed a lot over these 12 years to determine ST2 as a clinically invaluable biomarker for coronary heart failure affected person administration,” states Dr. Snider. “With this monetary infusion we will now full the effort.”

About ST2

ST2 is a soluble protein expressed by the guts in response to illness or damage. It is reflective of ventricular transforming and cardiac fibrosis related to coronary heart failure. ST2 will not be adversely affected by confounding components resembling age, body mass index and impaired renal perform. ST2 ranges change shortly in response to modifications within the coronary heart failure affected person’s situation.

About Critical Diagnostics

Critical Diagnostics (www.criticaldiagnostics.com) develops novel biomarkers to assist physicians optimize affected person care in cardiovascular illnesses, whereas containing healthcare prices. Critical Diagnostics has distribution companions in 50 international locations, overlaying two-thirds of the world’s inhabitants.

Critical Diagnostics
Dennis Dalangin
+1 (877) 700-1250
ddalangin@criticaldiagnostics.com

This article sources data from VentureBeat